News und Analysen
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th, at 10:30
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of
Entdecke das Naturwunder: Egmont Honey Manuka Honig MGO 829+ UMF 20+ zum unschlagbaren Preis!
Johnson & Johnson is as Cheap as it’s Going to Get
Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading
S&P 500's surge to new highs: Bull trap hiding in plain sight?
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.
The market went back into rally
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers Squibb Company (NYSE: BMY) is on a buying spree, announcing two acquisitions in less than a week.
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc.
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel
German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet
MOUNTAIN VIEW und SAN FRANCISCO, KALIFORNIEN / ACCESSWIRE / 11. Mai 2023 / Die German International School of Silicon Valley (GISSV) wurde im Rahmen des von der Deutschen Industrie- und
Vamorolone NDA Mid-Cycle Review Meeting durch FDA abgeschlossen
Pratteln, Schweiz, und Rockville, MD, USA, 25. April 2023 -- Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. geben bekannt, dass die U.S.-Gesundheitsbehörde FDA das Mid-Cycle
